{"id":110855,"date":"2020-08-04T07:29:55","date_gmt":"2020-08-04T14:29:55","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/08\/avalon-globocare-successfully-completes-phase-i-first-in-human-clinical-study-of-its-leading-chimeric-antigen-receptor-car-t-cell-therapy-candidate"},"modified":"2020-08-04T07:29:55","modified_gmt":"2020-08-04T14:29:55","slug":"avalon-globocare-successfully-completes-phase-i-first-in-human-clinical-study-of-its-leading-chimeric-antigen-receptor-car-t-cell-therapy-candidate","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/08\/avalon-globocare-successfully-completes-phase-i-first-in-human-clinical-study-of-its-leading-chimeric-antigen-receptor-car-t-cell-therapy-candidate","title":{"rendered":"Avalon GloboCare successfully completes Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/avalon-globocare-successfully-completes-phase-i-first-in-human-clinical-study-of-its-leading-chimeric-antigen-receptor-car-t-cell-therapy-candidate3.jpg\"><\/a><\/p>\n<p><b><a href=\"https:\/\/ca.proactiveinvestors.com\/companies\/news\/922794\/avalon-globocare-forges-partnership-with-austrian-university-to-develop-coronavirus-vaccine-922794.html\" target=\"_blank\">READ: Avalon GloboCare forges partnership with Austrian university to develop coronavirus vaccine<\/a><\/b><\/p>\n<p>It noted that treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>READ: Avalon GloboCare forges partnership with Austrian university to develop coronavirus vaccine It noted that treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-110855","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/110855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=110855"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/110855\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=110855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=110855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=110855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}